Work

Sequential delivery of eosinophil cationic protein and interleukin-4 enhances their therapeutic efficacy for myocardial infarction

Year: 2026
Type: article
Abstract: Eosinophils protect heart from post-myocardial infarction (MI) injury via cationic protein (ECP) and interleukin-4 (IL-4). Here we engineered and optimized a cell-free therapy for MI via regulated delivery of ECP and IL-4. Pluronic F127 thermosensitive hydrogels embedded with gelatin methacryloyl microspheres (GMs) were constructed for sequential ECP and IL-4 delivery. Immediately following MI, mice received an intrapericardial injection of therapeutic formulations. At 3 days post-MI, codelivery of ECP and IL-4 limited infarct size and preserved cardiac function. Rapid ECP release followed by sustained IL-4 release (IL-4@GM + ECP) yielded the most favorable outcomes with attenuated cardiomyocyte apoptosis and enhanced M2 macrophage contents in post-MI hearts. At 28 days post-MI, IL-4@GM + ECP exhibited robust cardiac functional recovery and cardiac geometry maintenance with minimal fibrotic scarring. Microfil perfusion imaging revealed that IL-4@GM + ECP enhanced angiogenesis with abundant perfused neovessels in the infarcts. Matrigel plug assays confirmed that codelivery of ECP and IL-4 yielded mature and tight vessel structures with CD31 + endothelial cell (EC) lumens surrounded by α-SMA + smooth muscle cells (SMCs) and PDGFR-β + pericytes. Mechanistic studies demonstrated that ECP induced angiogenesis by enhancing EC proliferation, migration, and cellular junctions. Conversely, IL-4 disrupted endothelial junctions but enhanced SMC migration to stabilize nascent endothelium. Sequential delivery of ECP and IL-4 helps generate functional neovessels. The therapeutic efficacy of IL-4@GM + ECP in MI was validated in eosinophil-deficient ΔdblGATA mice. In summary, rapid ECP release, followed by sustained IL-4 release effectively improved cardiac function post-MI by orchestrating neovessel formation, providing a cell-free alternative to eosinophil-based cell therapy for MI.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W7236262957
FWCI:
Cites: 67
Cited by:
Related to: 10